Dmitry M Hushpulian
Overview
Explore the profile of Dmitry M Hushpulian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soni P, Kaidery N, Sharma S, Gazaryan I, Nikulin S, Hushpulian D, et al.
Front Pharmacol
. 2024 Jul;
15:1390798.
PMID: 39040474
Neurodegenerative diseases represent a pressing global health challenge, and the identification of novel mechanisms underlying their pathogenesis is of utmost importance. Ferroptosis, a non-apoptotic form of regulated cell death characterized...
2.
Shaposhnikov L, Chikurova N, Atroshenko D, Savin S, Kleymenov S, Chernobrovkina A, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203708
Ribonucleoside hydrolase C (RihC, EC 3.2.2.1, 3.2.2.2, 3.2.2.3, 3.2.2.7, 3.2.2.8) belongs to the family of ribonucleoside hydrolases Rih and catalyzes the cleavage of ribonucleosides to nitrogenous bases and ribose. RihC...
3.
Hushpulian D, Kaidery N, Dutta D, Sharma S, Gazaryan I, Thomas B
Bioessays
. 2023 Nov;
46(1):e2300176.
PMID: 37919861
The transcription factor Nrf2 is the master regulator of cellular stress response, facilitating the expression of cytoprotective genes, including those responsible for drug detoxification, immunomodulation, and iron metabolism. FDA-approved Nrf2...
4.
Popov A, Kozlovskaya E, Klimovich A, Rutckova T, Vakhrushev A, Hushpulian D, et al.
Mar Drugs
. 2023 Sep;
21(9).
PMID: 37755083
The carotenoids mixture (MC) isolated from the starfish contains more than 50% astaxanthin, 4-6% each zeaxanthine and lutein, and less pharmacologically active components such as free fatty acids and their...
5.
Poloznikov A, Nikulin S, Hushpulian D, Khristichenko A, Osipyants A, Asachenko A, et al.
Antioxidants (Basel)
. 2022 Feb;
11(2).
PMID: 35204103
To evaluate the differences in action of commercially available 2-oxoglutarate mimetics and "branched-tail" oxyquinoline inhibitors of hypoxia-inducible factor prolyl hydroxylase (HIF PHD), the inhibitors' IC values in the activation of...
6.
Ahuja M, Kaidery N, Attucks O, McDade E, Hushpulian D, Gaisin A, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(45).
PMID: 34737234
7.
Gaisina I, Hushpulian D, Gaisin A, Kazakov E, Kaidery N, Ahuja M, et al.
Neurochem Int
. 2021 Jul;
149:105148.
PMID: 34329734
Aspirin is a desired leaving group in prodrugs aimed at treatment of neurodegeneration and other conditions. A library of aspirin derivatives of various scaffolds potentially activating Nrf2 has been tested...
8.
Hushpulian D, Kaidery N, Ahuja M, Poloznikov A, Sharma S, Gazaryan I, et al.
Front Aging Neurosci
. 2021 Apr;
13:673205.
PMID: 33897412
The Keap1-Nrf2 signaling axis is a validated and promising target for cellular defense and survival pathways. This minireview discusses the potential off-target effects and their impact on future drug development...
9.
Poloznikov A, Nersisyan S, Hushpulian D, Kazakov E, Tonevitsky A, Kazakov S, et al.
Front Pharmacol
. 2021 Feb;
11:621054.
PMID: 33584306
The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin...
10.
Nikulin S, Alekseev B, Sergeeva N, Karalkin P, Nezhurina E, Kirsanova V, et al.
Biochimie
. 2020 Oct;
179:217-227.
PMID: 33098909
Epigenetic alterations represent promising therapeutic targets in cancer treatment. Recently it was revealed that small molecules have the potential to act as microRNA silencers. Capacity to bind the discrete stem-looped...